Targeted Therapies With no Compromise
PDC Therapeutics is a clinical-stage biotechnology start-up developing smart nanomedicines for targeted therapies.
Superior Therapeutic Index
SagittaTM Bir and SagittaTM Dui are discovered to address this challenge with biodegradable conjugation platforms that reinforce ideal performances in terms of the therapeutic index, PK and manufacturability.
Targeted Therapies With no Compromise
PDC Therapeutics is a clinical-stage biotechnology start-up developing smart nanomedicines for targeted therapies.
Superior Therapeutic Index
SagittaTM Bir and SagittaTM Dui are discovered to address this challenge with biodegradable conjugation platforms that reinforce ideal performances in terms of the therapeutic index, PK and manufacturability.
PDC Therapeutics announces poster presentation at the ESMO 2022 Congress
PDC Therapeutics, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted therapies, announced the acceptance of a poster presentation at the ESMO 2022 Congress on 9-13 September 2022 in Paris – France.
Building better docetaxel therapy with nanocarrier technology, covered by BioWorld
PDC Therapeutics SA has passed the first test of its novel nanocarrier technology, getting approval to move up from the initial dose in the phase I trial of lead product RS-0139, which targets a docetaxel payload to tumors expressing the integrin receptor.
